Rhabdomyolysis Associated with Ziprasidone.
- Author:
Young Kyung SUNWOO
1
;
Sang Hun LEE
;
Min Hee KANG
;
Chul Eung KIM
;
Jeong Seop LEE
;
Jae Nam BAE
Author Information
1. Department of Psychiatry, College of Medicine, Inha University, Incheon, Korea. jnbae@inha.ac.kr
- Publication Type:Case Report
- Keywords:
Ziprasidone;
Rhabdomyolysis;
Creatine kinase;
Neuroleptic malignant syndrome (NMS)
- MeSH:
Antipsychotic Agents;
Creatine Kinase;
Dystonia;
Humans;
Leukocytes;
Male;
Neuroleptic Malignant Syndrome;
Psychotic Disorders;
Rhabdomyolysis*;
Young Adult
- From:Korean Journal of Psychopharmacology
2007;18(3):181-184
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We describe a case report of a young male patient with rhabdomyolysis associated with the use of atypical antipsychotic medication ziprasidone. A 23-year-old male was diagnosed with psychotic disorder not otherwise specified and treated with ziprasidone 120 mg a day. On hospital day 6, the patient developed acute dystonia. On day 8, the serum creatine kinase (CK) level was markedly elevated up to 53,880 IU/L, and a white blood cell (WBC) count was 10,500 cells/microliter. No other diagnostic criteria for neuroleptic malignant syndrome (NMS) were present. On discontinuation of the drug, serum CK concentrations returned to normal within 10 days. Atypical NMS should be considered when patients was treated with novel atypical antipsychotics who develop isolated serum CK elevation.
